An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

Inclusion Criteria: * HIV positive * Have a CD4 cell count of 300 cells/mm3 or more within 45 days of study entry * Are on combination anti-HIV therapy or are beginning anti-HIV therapy at the time of study entry * Are at least 18 years old Exclusion Criteria: * Have received IL-2 before * Have cancer requiring chemotherapy * Have evidence of active clinical disease within the past year for any AIDS-defining illness or certain other conditions such as herpes zoster or Chagas disease. (This study has been changed. Previously, patients were ineligible if they had a history of any AIDS-defining illness or certain other conditions.) * Have used certain medications, such as corticosteroids or drugs affecting the immune system, in the 45 days before study entry * Have a nervous system disorder requiring antiseizure medication * Have an autoimmune or inflammatory disease such as inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), psoriasis, optic neuritis, or any autoimmune/inflammatory diseases with potentially life-threatening complications * Are pregnant or breastfeeding